FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

nington, D.C. 20549	ОМВ	== 3
		_

	UNID APPRO	JVAL		
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP	OMB Number:	3235-0287		
OTATEMENT OF OTTATOLO IN BENEFICIAL OWNERORIII	Estimated average burden			

hours per response:

0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* ABERCROMBIE GEORGE B					BIG	2. Issuer Name and Ticker or Trading Symbol BIOCRYST PHARMACEUTICALS INC [BCRX]									eck all appli	cable) or	Pers	son(s) to Iss	wner
(Last) PO BOX	`	(First) (Middle)				3. Date of Earliest Transaction (Month/Day/Year) 06/13/2023									Officer (give title Other of below)				pecify
(Street) CHAPEL HILL NC 27516			_ 4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City) (State) (Zip)				Ru	Rule 10b5-1(c) Transaction Indication														
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.										d to									
		Tab	le I - No	n-Deri\	/ative	Se	curities	s Ac	quired, I	Disp	osed c	of, or B	ene	ficial	y Owned	t			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da					r) E	A. Deeme execution f any Month/Day	Date,	3. 4. Securities Acquired Disposed Of (D) (Instr. 8)			3, 4 and Secur Benet Owne		es ally Following	Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
								Code	v	Amount	(A) (D)	or	Price	Transac	Reported Transaction(s) (Instr. 3 and 4)			(111501.4)	
Common Stock 06/13/2			3/2023	/2023 A 16,745 ⁽¹⁾ A			\$0	\$0 29,611			D								
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	Date,	4. Transac Code (Ir 8)		n of		6. Date Exe Expiration (Month/Day	Date	Amount of			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction((Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisabl		xpiration ate	Title	or Nu of	umber					
Automatic Stock Option Grant ⁽²⁾	\$8.18	06/13/2023			A		39,072		06/13/2024	1 00	6/13/2033	Commor Stock	39	9,072	\$0	39,072		D	

Explanation of Responses:

- 1. Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.
- $2. \ Automatic \ non-employee \ director \ grant \ of \ stock \ options \ pursuant \ to \ the \ Director \ Compensation \ Policy.$

/s/ Alane P. Barnes, by power of attorney

06/15/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.